Next Science (ASX:NXS) share price jumps on record revenue growth

A surge in revenue during the first half of 2021 puts the Next Science share price in the green today…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Next Science Ltd (ASX: NXS) share price is charging higher today.

At the time of writing, the medical technology company's shares are up 4.05% to $1.54.

medical doctor performing surgery using surgical instruments

Image source: Getty Images

Why is the Next Science share price rallying today?

Investors are looking at the Next Science share price more optimistically following the release of its second quarter update.

According to the release, the company pulled in US$3.9 million in revenue for the first half. This reflected an increase of 271% on the prior corresponding period.

Pleasingly for shareholders, this was a record rate of growth from Next Science.

Additionally, its XPerience No Rinse Antimicrobial Solution was cleared by the United States Food and Drug Administration.

The solution helps prevent surgical site biofilm based infections.

The approval process for use in US hospitals is now underway.

Furthermore, Next Science's antimicrobial wound gel, BlastX returned to the company and sales commenced.

Next Science regained the global distribution rights to BlastX from 3M (NYSE: MMM) in April 2021.

The patented medical product has also received approval from Australia's Therapeutic Goods Administration (TGA).

After burning through US$1.9 million in cash during the first half, the company maintains US$13.2 million cash on hand.

Managing Director commentary

Managing Director, Judith Mitchell spoke about the record result for the company:

The strategies we are executing to commercialise our proprietary Xbio technology platform are delivering record results. The 271% revenue growth we have reported for 1H was driven by sales from our existing products.

Following the approval of our market leading "no rinse antimicrobial solution", XPerience, by the FDA on 23 April, we are building an excellent platform for future growth. Our focus has been to secure VAC approvals across US hospitals to facilitate commercial sales in the US. As at mid-July, we had made 123 VAC submissions covering 211 hospitals and we had received 20 approvals.

Next Science share price snapshot

Thanks to today's gains, the Next Science share price is 18.46% higher over the past year.

However, investors who bought at the 52-week high of $2.06 in June are still down 25.24%.

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Next Science Limited. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

An arrogant banker pleased with himself and his success winks at his mobile phone while taking a selfie.
Financial Shares

5 best ASX 200 financial shares of FY26

ASX 200 financials went from being the best sector of FY25 to negative growth in FY26.

Read more »

Three satisfied miners with their arms crossed looking at the camera proudly.
Resources Shares

5 best ASX 200 mining shares of FY26

We explain why these 5 mining stocks experienced the highest capital growth last year.

Read more »

Ten smiling business people wave to the camera after receiving some winning company news.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a very happy Friday indeed on the ASX.

Read more »

A woman holds a tape measure against a wall painted with the word BIG.
Share Gainers

6 ASX 200 large-cap shares that rose 60% to 275% in FY26

Large-cap stocks are worth $10 billion or more. These were last year's top 6 gainers.

Read more »

Three trophies in declining sizes with a red curtain backdrop.
Share Gainers

3 ASX 200 stocks storming higher this week on big announcements

Investors sent these three stocks rocketing 15% to 37% this week. But why?

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Energy Shares

Boss Energy shares surging 12% today on big uranium news

Investors are piling into Boss Energy shares on Friday. But why?

Read more »

Two players on a field pump their fists in the air, indicating two of the best
ASX Share Market News

Top ASX 200 share of each market sector in FY26

These stocks were the outperformers across the 11 market sectors last year.

Read more »

Ten happy friends leaping in the air outdoors.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a lacklustre Thursday session for investors.

Read more »